Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  2. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  3. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  4. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  5. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  6. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  7. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  8. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  9. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  10. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  11. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  12. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  13. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  14. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  15. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  16. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  17. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  18. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  19. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  20. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  21. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  22. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  23. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  24. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  25. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  26. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  27. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  28. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  29. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  30. Pleuger C, et al. 2022. Elife. 11: . PubMed
  31. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  32. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  33. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  34. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  35. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  36. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  37. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  38. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  39. Rosain J, et al. 2023. Cell. 186:621. PubMed
  40. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  41. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  42. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  43. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  44. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  45. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  46. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  47. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  48. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  49. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  50. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  51. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  52. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  53. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  54. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  55. Zhao Y, et al. 2022. J Neurosci. . PubMed
  56. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  57. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  58. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  59. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  60. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  61. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  62. Han X, et al. 2022. Nutrients. 14:. PubMed
  63. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  64. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  65. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  66. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  67. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  68. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  69. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  70. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  71. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  72. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  73. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  74. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  75. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  76. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  77. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  78. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  79. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  80. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  81. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  82. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  83. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  84. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  85. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  86. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  87. Imai H, et al. 2023. iScience. 26:106822. PubMed
  88. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  89. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  90. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  91. Wu L, et al. 2023. Cell Res. . PubMed
  92. Cansever D, et al. 2023. Nat Immunol. . PubMed
  93. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  94. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  95. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  96. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  97. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  98. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  99. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  100. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  101. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  102. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  103. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  104. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  105. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  106. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  107. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  108. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  109. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  110. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  111. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  112. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  113. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  114. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  115. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  116. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  117. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  118. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  119. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  120. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  121. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  122. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  123. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  124. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  125. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  126. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  127. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  128. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  129. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  130. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  131. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  132. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  133. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  134. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  135. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  136. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  137. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  138. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  139. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  140. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  141. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  142. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  143. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  144. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  145. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  146. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  147. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  148. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  149. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  150. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  151. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  152. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  153. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  154. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  155. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  156. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  157. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  158. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  159. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  160. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  161. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  162. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  163. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  164. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  165. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  166. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  167. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  168. Woodruff MC, et al. 2022. Nature. :. PubMed
  169. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  170. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  171. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  172. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  173. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  174. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  175. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  176. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  177. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  178. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  179. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  180. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  181. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  182. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  183. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  184. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  185. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  186. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  187. Akiyama H, et al. 2020. J Virol. . PubMed
  188. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  189. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  190. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  191. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  192. Mills C, et al. 2022. Cells. 11:. PubMed
  193. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  194. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  195. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  196. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  197. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  198. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  199. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  200. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  201. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  202. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  203. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  204. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  205. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  206. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  207. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  208. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  209. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  210. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  211. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  212. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  213. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  214. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  215. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  216. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  217. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  218. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  219. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  220. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  221. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  222. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  223. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  224. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  225. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  226. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  227. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  228. Wang Z, et al. 2021. bioRxiv. . PubMed
  229. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  230. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  231. English KG, et al. 2022. Biomedicines. 10:. PubMed
  232. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  233. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  234. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  235. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  236. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  237. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  238. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  239. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  240. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  241. Woodruff M, et al. 2020. medRxiv. . PubMed
  242. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  243. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  244. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  245. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  246. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  247. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  248. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  249. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  250. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  251. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  252. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  253. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  254. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  255. Popay TM, et al. 2021. Elife. 10: . PubMed
  256. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  257. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  258. Elias G, et al. 2022. Elife. 11:. PubMed
  259. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  260. Ito Y, et al. 2018. Cell. 174:636. PubMed
  261. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  262. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  263. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  264. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  265. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  266. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  267. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  268. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  269. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  270. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  271. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  272. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  273. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  274. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  275. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  276. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  277. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  278. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  279. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  280. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  281. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  282. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  283. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  284. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  285. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  286. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  287. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  288. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  289. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  290. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  291. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  292. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  293. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  294. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  295. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  296. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  297. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  298. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  299. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  300. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  301. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  302. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  303. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  304. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  305. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  306. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  307. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  308. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  309. Dudek M, et al. 2021. Nature. 592:444. PubMed
  310. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  311. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  312. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  313. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  314. He Y, et al. 2022. Cells. 11:. PubMed
  315. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  316. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  317. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  318. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  319. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  320. Wang Z, et al. 2021. Nature. 592:616. PubMed
  321. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  322. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  323. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  324. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  325. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  326. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  327. Wang Z, et al. 2021. Nature. 595:426. PubMed
  328. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  329. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  330. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  331. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  332. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  333. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  334. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  335. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  336. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  337. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  338. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  339. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  340. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  341. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  342. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  343. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  344. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  345. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  346. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  347. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  348. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  349. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  350. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  351. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  352. Korin B, et al. 2020. Sleep. :43. PubMed
  353. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  354. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  355. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  356. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  357. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  358. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  359. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  360. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  361. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  362. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  363. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  364. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  365. Viant C, et al. 2020. Cell. 183:1298. PubMed
  366. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  367. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  368. Gaebler C, et al. 2020. bioRxiv. . PubMed
  369. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  370. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  371. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  372. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  373. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  374. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  375. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  376. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  377. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  378. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  379. Spath S, et al. 2022. iScience. 25:104998. PubMed
  380. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  381. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  382. Sibler E, et al. 2021. Cells. 10:. PubMed
  383. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  384. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  385. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  386. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  387. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  388. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  389. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  390. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  391. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  392. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  393. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  394. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  395. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  396. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  397. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  398. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  399. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  400. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12.18.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account